ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.

A. Guasch,1 H. Xu,2 A. Mehta,1 A. Ghali,1 S. Mead,1 H. Gebel,1 R. Bray,1 C. Larsen,1 T. Pearson,1 A. Kirk.2

1Emory Transplant Center, Atlanta, GA
2Duke University, Durham, NC.

Meeting: 2016 American Transplant Congress

Abstract number: 283

Keywords: Co-stimulation, Immunosuppression, Kidney transplantation

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: Belatacept and Steroid Withdrawal in Kidney Transplantation

Session Time: 4:30pm-6:00pm

 Presentation Time: 4:30pm-4:42pm

Location: Ballroom A

Related Abstracts
  • Deceased Donor Kidney Transplantation Without Calcineurin Inhibitors or Steroids
  • Investigating Posttransplant Allo-Donor Specific CD57+ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.

Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but its clinical use has been hampered by early, high-grade acute rejections. We have reported that a regimen including a single intraoperative dose of alemtuzumab followed by monthly belatacept and daily sirolimus can prevent rejection of live (LD) or deceased (DD) donor kidney transplants, including allosensitized individuals and recipients of extended criteria donor (ECD) kidneys. Herein we report the follow-up on the initial 40 patient cohort. Graft and patient survival remains 100%. One patient withdrew from protocol due to pregnancy; 39 patients remain on protocol, all of who have enjoyed stable and excellent graft function. The trial enrolled in two cohorts of 20. Median follow-up in cohort 1 (all LD) is > 60 months with a mean creatinine of 1.20 mg/dl. Median follow-up in cohort 2 (LD, DD, ECD) is 24 months with a mean creatinine of 1.4 mg/dl. Three patients in each cohort have been intolerant to sirolimus, requiring conversion to mycophenolate. In cohort 1, 6 of 20 patients were weaned to monotherapy belatacept with follow-up on monotherapy exceeding 3 years, and in cohort 2, 4 patients have been weaned to monotherapy belatacept with a mean follow up on monotherapy of 6 months. Additional patients are approaching eligibility for sirolimus withdrawal. Mechanistic study of all patients indicate that post depletional repopulation under this regimen facilitates significant (p<0.01) enrichment for naïve CD28+ T cells, reduction of CD28- T memory cells, and augmentation of regulatory T and B cell phenotypes; all characteristics that favor belatacept-based immunosuppression. Recipients exhibit donor-specific hyporesponsiveness without impaired CMV or EBV-specific immunity. Continued follow-up of this pilot experience indicates that belatacept and sirolimus effectively prevent kidney allograft rejection without CNIs or steroids when used following alemtuzumab induction, and provides insight as to the etiology of early belatacept-resistant rejection. Prospective controlled trials of this regimen using broad inclusion criteria are warranted.

CITATION INFORMATION: Guasch A, Xu H, Mehta A, Ghali A, Mead S, Gebel H, Bray R, Larsen C, Pearson T, Kirk A. A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Guasch A, Xu H, Mehta A, Ghali A, Mead S, Gebel H, Bray R, Larsen C, Pearson T, Kirk A. A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/a-pathway-to-belatacept-monotherapy-alemtuzumab-belatacept-and-rapamycin-for-kidney-transplantation/. Accessed March 3, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.